Sanofi-aventis Korea announced that the next generation of long-term basic insulin TJEZO Solostar (component name: insulin glazin, 300 U / mL gene recombination) in the first week of October at the annual conference of the European Diabetes Society (EASD) have been published and it has been shown that patients titrating their blot may have more effective control of blood glucose compared to patients receiving a sufficient dose under the supervision of the physician.
According to the TAKE CONTROL study, the number of patients with mean glycosylated hemoglobin (HbA1c) that reached the target blood glucose of less than 7% was found to be higher in self-defined patients than in the appropriate patients under the leadership the primary caregiver. In addition, the number of patients achieving the fasting blood glucose target without hypoglycaemia (<3.0 mmol / L) or severe hypoglycemia requiring medical support (67% vs. 58%) was also determined by the patient.
During the study period, the degree of reduction in the psychological burden was similar in both groups and the number of patients who reported having a high psychological weight after 24 weeks was lower in patients dosed sufficiently by those responsible for 8.5 % versus 12.2%).
David Russell Jones of the TAKE CONTROL study Professor of Diabetes and Endocrinology at Royal Surry County Hospital, Surrey University, United Kingdom "Many diabetics suffer from hypoglycemia, a major barrier to adherence to treatment," said TAKE CONTROL. The newly developed insulin base such as Tuzeo has been shown to help patients better control their blood sugar levels. "
Meanwhile, the TAKE CONTROL study was conducted in 631 adult type 2 diabetic patients whose glucose levels were not adequately controlled with Tozeol for 24 weeks. We compared the efficacy and safety of Tuzeo when the patient himself administered the dose titration and when the person who handled it handled it.
<© 2018 메디파나뉴스, 무단 전재 및 배포금지>"The Center for Korean Pharmaceutical News" MEDIPANA NEWS